Regardless of the precise mechanism, sigma-2/PGRMC1 selective small molecule antagonists have the potential to be disease-modifying therapeutics for Alzheimer's disease patients. This evidence concerns the gene AP2S1 and early-onset autosomal dominant Alzheimer disease.